MOMIPP
Modify Date: 2024-01-02 20:55:45
MOMIPP structure
|
Common Name | MOMIPP | ||
|---|---|---|---|---|
| CAS Number | 1363421-46-8 | Molecular Weight | 292.33 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C18H16N2O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of MOMIPPMOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB)[1][2]. |
| Name | trans-3-(5-methoxy-2-methyl-1H-indol-3-yl)-1-(4-pyridinyl)-2-propen-1-one |
|---|---|
| Synonym | More Synonyms |
| Description | MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB)[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | MOMIPP can induce intense macropinocytosis, leading to methuosis in cultured glioblastoma cells at low micromolar concentrations[1]. In U373 and Hs683 cell lines, 3 µM for MOMIPP induces cell vacuolization[1]. MOMIPP (10 μM) causes early disruptions of glucose uptake and glycolytic metabolism. MOMIPP selectively activates the JNK1/2 stress kinase pathway, resulting in phosphorylation of c-Jun, Bcl-2 and Bcl-xL[2]. Western Blot Analysis[2] Cell Line: U251 cells Concentration: 10 μM Incubation Time: 4 h or 24 h Result: Activated the JNK stress kinase pathway. |
| In Vivo | MOMIPP (80 mg/kg; i.p.; once daily; for 15 consecutive days) shows moderately effective in suppressing progression of intracerebral glioblastoma xenografts[2]. Animal Model: Athymic CrTac:NCR-Foxn1 mice (female, 7-8 weeks)[2] Dosage: 80 mg/kg Administration: i.p.; once daily; for 15 consecutive days Result: Suppressed progression of intracerebral glioblastoma xenografts. |
| References |
| Molecular Formula | C18H16N2O2 |
|---|---|
| Molecular Weight | 292.33 |
| Exact Mass | 292.12100 |
| PSA | 54.98000 |
| LogP | 3.77600 |
| trans-3-(5-methoxy-2-methylindol-3-yl)-1-(4-pyridinyl)-2-propen-1-one |